Telesis Bio Q4 revenue down 26% YoY to $7.0M; net loss widens to $18.3M; BioXp kits hit record $1.0M

Telesis Bio Inc.

Revenue $7.0M in Q4 2023, down 26% YoY from $9.5M; full-year $27.5M flat.
Net loss $18.3M ($0.61/share) vs $8.1M ($0.28) prior year Q4; includes $11.4M goodwill impairment.
BioXp kit sales record >$1.0M in Q4, up 59.6% QoQ and 25.9% YoY; mRNA workflow sales grew >300%.
Operating expense (excl impairment) down 24.4% to $10.8M; headcount reduced from 190 to 138.
Cash and investments $19.3M at Dec 31, 2023; long-term notes payable $5.3M after $15M repayment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Telesis Bio Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Telesis Bio Inc. (“the Company”) issued a press release (the “Earnings Release”) announcing results for the quarter and year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-038056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.